What is Vipdomet?
Vipdomet is a dual-action treatment for type-2 diabetes. Containing metformin and alogliptin (a DPP-4 inhibitor), it works in a few different ways to help lower your blood sugar when lifestyle changes and metformin alone haven't worked to keep your blood sugar levels at a healthy level.
Type-2 diabetes is a condition that’s usually developed in adulthood. It happens when your pancreas is no longer able to secrete as much insulin as it should, or when your cells have lost sensitivity to insulin. Insulin is an essential hormone for moving sugar from your bloodstream into your cells for it to be used as energy. When you’re not able to do this as well as you should do, high concentrations of glucose (sugar) build up in your bloodstream, which can lead to long-term problems for your health.
How does Vipdomet work?
Vipdomet’s two active ingredients work together to help lower your blood sugar. Metformin is the most commonly prescribed ‘first-line’ treatment for type-2 diabetes, and it mostly works by helping your body to use insulin better, as well as reducing the amount of glucose that’s produced in your liver and delaying the amount of glucose that’s absorbed from the food you eat.
Alogliptin, a DPP-4 inhibitor, helps your pancreas to secrete more insulin. It does this by extending the action of hormones called ‘incretins’, which stimulate your pancreas to secrete insulin. Incretins are broken down by enzymes in your body, which alogliptin reduces the action of. This then allows incretins to remain active in your system for longer, which increases your insulin secretion as a result.
What doses of Vipdomet are there?
Vipdomet is available in two doses. Both doses of Vipdomet contain 12.5mg of alogliptin, but the lower dose treatment contains 850mg of metformin, whereas the higher dose tablet has 1,000mg.
The recommended dose is to take one tablet twice a day, but this might be lower if you have kidney problems.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.